Bronchiolitis obliterans organizing pneumonia (BOOP)

Also known as cryptogenic organizing pneumonia, bronchiolitis obliterans organizing pneumonia, or BOOP, is an uncommon condition that affects the lungs. It happens when the bronchioles or small airways of the lungs, along with the alveoli or tiny air-exchange sacs become clogged up and inflammed with connective tissue.

Symptoms are generally pretty mild, ranging from an unproductive cough to shortness of breath. Symptoms are not always immediately present.

While there are many reasons a person may develop BOOP, for the sake of this entry we will look at BOOP as a consequence of anti-cancer treatment. Specifically, BOOP sometimes develops as a complication of a bone marrow transplantation.

BOOP in HSCTs

Bronchiolitis obliterans organizing pneumonia occurrs to between 2-14 % of all allogeneic bone marrow transplantation patients.

The factors that raise the risk of BOOP developing in these patients are

- Chronic GVHD
- Low immunoglobulin levels

Typically, BOOP would be treated with corticosteroid therapy, but in bone marrow transplant patients, response is considered pretty poor. Neither the corticosteroids nor bronchodilators can reliably improve the airflow through the lungs.

Therefore a prompt response to BOOP is critical for the patient's prognosis because there's no telling what kind of clinical course BOOP may take. In patients with advanced disease, a lung transplantation may become necessary.

Sources

- Boyiadzis, Michael M. et al. Hematology-Oncology Therapy. 2007. New York: McGraw Hill, Medical Publishing Division.
- Epler, Gary R MD. Bronchiolitis obliterans organizing pneumonia. Arch Intern Med. Vol 161 Jan22 2001.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap